[1] 李力,顾晓红. 血清IL-6和IL-8在还原型谷胱甘肽治疗肝硬化患者前后的变化. 实用肝脏病杂志,2005,8(5):274-275. [2] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2010年版). 实用肝脏病杂志,2011,14(2):81-89. [3] Wajner SM,Maia AL. New insights toward the acute non-thyroidal illness syndrome.Front Endocrinol,2012,3(8): 1-7. [4] 王海霞,赵强,谢俊强. 慢性乙型重型肝炎患者血清甲状腺激素测定的临床意义. 肝脏,2006,11(4):295-296. [5] 陈琳,王峰,倪丽萍,等. 肝病患者110例血清甲状腺相关物质的检测及临床意义. 南通大学学报(医学版),2006,26(4):265-267. [6] Yang R,Shan ZY,Li YS,et al. Prevalence of thyroid autoantibodies in hepatitis C and hepatits B infection in China.Intern Med,2011,50(8):811-815. [7] 余雪平, 苏智军, 郭如意, 等. 慢性乙型肝炎患者外周血Treg/Th17检测及其意义. 福建医科大学学报,2012,46(2):123-126. [8] Wang QH,Zheng YH,Huang ZM et al. Activated IL-23/IL-17 pathway closely correlates with increased Foxp3 expression in livers of chronic hepatitis B patients. BMC Immunol,2011,12(25):1472-1481. [9] Su ZJ,Yu XP,Guo RY,et al. Changes of balance between Treg and Th17 cells in patients with chronic hepatitis B. Diagn Micr Infec Dis,2013,76(4):437-444. [10] 王旭,张会英. 甲状腺自身抗体定量检测的临床应用. 中国实验诊断学,2010,14(8):1249-1251. [11] 孙春玲,查莉,张佩华. 关于促甲状腺素受体抗体的研究. 中国地方病防治杂志,2005,20(5):283-284. [12] Torpy DJ,Tsigos C,Lotsikas AJ,et al. Acute and delayed effects of a single-dose injection of interleukin-6 on thyroid function in healthy humans. Metabolism,1998,42(10):1289-1293. [13] 范思森,姜兰,李华甫,等. 慢性乙型肝炎病毒携带者血清IL-1、IL-6和CRP水平与肝组织学相关研究. 实用肝脏病杂志,2006,9(4):211-212. [14] 董吉祥,谢莹,汪寅,等.Graves病患者外周血IL-6、TNF-α水平表达的变化及意义. 中国免疫学杂志,2006,22(4):378-380. [15] Wang SH,Bretz JD,Phelps E,et al. A unique combination of inflammatory cytokines enhances apoptosis of thyroid follicular cells and transforms nondestructive to destructive thyroiditis in experimental autoimmune thyroiditis. J Immunol,2002,168(5):2470-2474. |